Skip to main content
Top
Published in: Clinical Rheumatology 4/2004

01-08-2004 | Case Report

Lupus anticoagulant, Factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis

Authors: Imad Uthman, Ismail Khalil, Raja Sawaya, Ali Taher

Published in: Clinical Rheumatology | Issue 4/2004

Login to get access

Abstract

We describe the case of a young Lebanese woman with systemic lupus erythematosus (SLE) and a positive lupus anticoagulant (LAC) who developed right internal jugular vein and sigmoid sinus thrombosis. Coagulation studies showed that in addition to the LAC the patient was heterozygous for the factor V (FV) Leiden mutation, and C677T mutation of the methylenetetrahydrofolate reductase gene. The high prevalence of FV Leiden in the eastern Mediterranean region suggests that we should probably screen our SLE patients in this area, especially those with anticardiolipin antibodies and/or LAC who have no history of thrombosis, for this and other thrombophilia markers. The detection of such abnormalities may have major practical consequences for the long-term management of these patients to prevent further thrombotic episodes.
Literature
1.
go back to reference Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 42:200–213 Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR (2003) Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 42:200–213
2.
go back to reference Levine SR, Kieran S, Puzio K, Feit H, Patel SC, Welch KM (1987) Cerebral venous thrombosis with lupus anticoagulants. Report of two cases. Stroke 18:801–804PubMed Levine SR, Kieran S, Puzio K, Feit H, Patel SC, Welch KM (1987) Cerebral venous thrombosis with lupus anticoagulants. Report of two cases. Stroke 18:801–804PubMed
3.
go back to reference Tomer Y, Kessler A, Eyal A, Many A, Shoenfeld Y (1991) Superior vena cava occlusion in a patient with antiphospholipid antibody syndrome. J Rheumatol 18:95–97PubMed Tomer Y, Kessler A, Eyal A, Many A, Shoenfeld Y (1991) Superior vena cava occlusion in a patient with antiphospholipid antibody syndrome. J Rheumatol 18:95–97PubMed
4.
go back to reference Cervera R, Piette JC, Font J et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed Cervera R, Piette JC, Font J et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019–1027CrossRefPubMed
5.
go back to reference Deschiens MA, Conard J, Horellou MH et al. (1996) Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27:1724–1730PubMed Deschiens MA, Conard J, Horellou MH et al. (1996) Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 27:1724–1730PubMed
6.
go back to reference Carhuapoma JR, Mitsias P, Levine SR (1997) Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28:2363–2369PubMed Carhuapoma JR, Mitsias P, Levine SR (1997) Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 28:2363–2369PubMed
7.
go back to reference Kenet G, Sadetzki S, Murad H et al. (2000) Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31:1283–1288PubMed Kenet G, Sadetzki S, Murad H et al. (2000) Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 31:1283–1288PubMed
8.
go back to reference Chopra N, Koren S, Greer WL et al. (2002) Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 29:1683–1688PubMed Chopra N, Koren S, Greer WL et al. (2002) Factor V Leiden, prothrombin gene mutation, and thrombosis risk in patients with antiphospholipid antibodies. J Rheumatol 29:1683–1688PubMed
9.
go back to reference Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A (2001) High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 86:723–724PubMed Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A (2001) High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 86:723–724PubMed
10.
go back to reference Irani-Hakime N, Tamim H, Kreidy R, Almawi WY (2000) The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 65:45–49CrossRefPubMed Irani-Hakime N, Tamim H, Kreidy R, Almawi WY (2000) The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 65:45–49CrossRefPubMed
Metadata
Title
Lupus anticoagulant, Factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis
Authors
Imad Uthman
Ismail Khalil
Raja Sawaya
Ali Taher
Publication date
01-08-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 4/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0893-8

Other articles of this Issue 4/2004

Clinical Rheumatology 4/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine